ImmunoGen Inc. (NASDAQ:IMGN)’s share price traded down 1.1% during mid-day trading on Friday . The stock traded as low as $2.75 and last traded at $2.77, with a volume of 329,468 shares changing hands. The stock had previously closed at $2.80.

Several equities analysts have issued reports on the stock. Zacks Investment Research raised shares of ImmunoGen from a “sell” rating to a “hold” rating in a research note on Tuesday, August 9th. Jefferies Group reaffirmed a “buy” rating and set a $6.00 price target (down from $13.00) on shares of ImmunoGen in a research note on Friday, August 5th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $7.00 price target on shares of ImmunoGen in a research note on Thursday, May 19th. Cantor Fitzgerald reaffirmed a “hold” rating on shares of ImmunoGen in a research note on Wednesday, June 8th. Finally, JPMorgan Chase & Co. set a $5.00 price target on shares of ImmunoGen and gave the stock a “hold” rating in a research note on Friday, August 5th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $11.72.

The firm’s 50-day moving average price is $2.94 and its 200 day moving average price is $5.57. The company’s market cap is $241.35 million.

ImmunoGen (NASDAQ:IMGN) last released its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by $0.12. During the same period in the previous year, the company earned ($0.35) EPS. The company earned $7.41 million during the quarter, compared to analyst estimates of $17.11 million. The company’s revenue was down 41.2% compared to the same quarter last year. On average, analysts predict that ImmunoGen Inc. will post ($1.61) earnings per share for the current fiscal year.

ImmunoGen, Inc (ImmunoGen) is a clinical-stage biotechnology company focused on the development of targeted anticancer therapeutics. The Company’s clinical and preclinical product candidates are antibody-drug conjugates (ADCs), which is a type of medicine that uses a monoclonal antibody to deliver a therapeutic agent to targeted cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.